What medtech SMEs can learn from the megadeals
To view our article on the Today’s Medical Developments Magazine website, click here.
If you run a medtech company doing $20 to $200 million in revenue, the 2026 deal headlines can read like dispatches from a different planet. Abbott closed its roughly $21 billion acquisition of Exact Sciences in March, entering cancer screening in a single stroke. In January, Boston Scientific agreed to buy Penumbra at an enterprise value near $14.5 billion. Big numbers, big logos, big narratives – and almost none of it maps to the decision on your desk.
That disconnect matters, because the megadeals are the least representative thing happening in the market. They’re the exception the industry writes about, not the pattern determining what happens to most companies that sell this year.
What the headlines actually obscure
Strip away the two or three transactions dominating the trade press, and a different picture emerges. Bain’s 2026 M&A report put it bluntly: headline acquisitions get the attention, but most aren’t building category leaders. That work, Bain argues, happens through serial, targeted, capability-building deals sharpening a specific edge – in robotics, diagnostics, imaging, or wherever the acquirer is trying to win. PwC’s outlook lands in the same place, expecting activity to center on capability-building acquisitions rather than transformational ones. At MedWorld Advisors, we’ve been speaking to this trend for some time as well.
And the data backs the framing. Medtech deal value did rise – roughly $80 billion in 2025, strong into the first half of 2026 – but a third of that strategic value came from spin-offs and divestitures, as the large players carved out non-core units to sharpen their focus. The acquisitions filling out the rest of the table weren’t billion-dollar swings. They were tuck-ins: J&J adding a radiofrequency guidewire to its cardiovascular line, or Haemonetics acquiring Vivasure after an earlier minority investment – the buyer already knew the asset.
What this means if you’re thinking about selling
The reframe for an owner is this: you’re not competing with Penumbra for a buyer’s attention, and shouldn’t try to. The companies getting bought in this market aren’t the ones with the most transformative story – they’re the ones completing a specific capability an acquirer has already decided it needs.
Three things to keep in mind:
Strategic fit beats scale.
A buyer reshaping its portfolio is looking for a defined gap – a procedure-enabling technology, a workflow layer, a platform extending an existing franchise. A $40 million company that precisely fills that gap is more acquirable than a larger one that doesn’t. Your job before a process is to know which acquirer’s gap you fill and articulate it in their language, not yours.
Evidence and clarity command the premium.
In a buyer’s market with reset valuations, capital flows to assets with defensible technology, repeatable revenue or proof of scalability, regulatory clarity, and a credible growth path. The companies facing tougher outcomes have delayed commercialization or can’t explain their strategic role crisply. Vague “huge addressable market” framing reads as risk; specific evidence reads as value.
Private equity is shaping the demand, not just the strategics.
Private equity is sitting on near-record dry powder and under pressure to deploy it, with healthcare and medtech high on the mandate list. That matters in two ways. First, sponsors are actively pursuing platform and add-on acquisitions – a buy-and-build mandate often values a smaller company because it bolts onto an existing platform, putting a financial buyer in direct competition with the strategics. Second, PE rewards the same fundamentals a strategic does, but through a returns lens: clean financials, recurring or contracted revenue, a defensible niche, and a management team willing to stay and grow post-close. Knowing whether your most natural buyer is a strategic or a financial sponsor changes how you position and who you approach. Ideally, with a good M&A advisor, you can maximize your exit value by engaging with both options in a true competitive M&A process.
The trickle-down that does reach you
The megadeals aren’t irrelevant to smaller companies – they’re just relevant indirectly. When Abbott or Boston Scientific absorbs a multibillion-dollar target, it signals where that acquirer believes growth lives: cancer diagnostics, vascular intervention, connected care. Around each of those bets, the same acquirer will spend the next several years doing exactly the kind of capability-building tuck-ins a company your size can be part of. The headline tells you the territory; the tuck-ins tell you the opportunity.
The takeaway for owners in the $20 to $200 million range is steadying rather than discouraging. You most likely won’t be the deal on the front page, and you don’t need to be. The market determining your outcome rewards focus, fit, and clarity – knowing exactly what you do well and whose strategy you complete. That’s a game a well-run smaller company can win. We live it every day. The megadeals aren’t the only scoreboard worth watching. And at MedWorld Advisors, we’ll be watching you win.
